VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Typhi strain Ty21a-LPS-Shigella
Vaccine Information
  • Vaccine Name: Typhi strain Ty21a-LPS-Shigella
  • Target Pathogen: Shigella
  • Target Disease: Shigellosis
  • Vaccine Ontology ID: VO_0004701
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector: Salmonella typhi vaccine vector
  • Preparation: Ty21a-Ss simultaneously expresses both homologous Ty21a and heterologous S. sonnei O-antigens (Dharmasena et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: Mice were immunized with vaccine candidate strains (Ty21a-Ss) or negative controls Ty21a alone and PBS (Dharmasena et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Immunized and control mice were challenged intraperitoneally, 2 weeks after final immunization, with ∼5 × 106 CFU/ml of freshly grown, mid-log-phase virulent S. sonnei strain 53GI in 0.25 ml (∼2 × 106 CFU per mouse) of 5% hog gastric mucin (Sigma) dissolved in sterile saline (i.e. approximately 100 times the 50% lethal infectious dose [LD50]) (Dharmasena et al., 2013).
  • Efficacy: Ty21a-Ss elicited strong dual anti-LPS serum immune responses and 100% protection in mice against a virulent S. sonnei challenge (Dharmasena et al., 2013).
References